Akkermansia Benefits: What the Human Research Shows

The main Akkermansia benefits being studied are support for the gut lining and for metabolic markers such as insulin sensitivity, cholesterol and weight maintenance. The human evidence is real but early: a handful of small trials, mostly of pasteurized cells, while several of the best-known claims, including the GLP-1 link, so far rest on mice or on subgroups of people. Here is what each benefit rests on, where the research stands, and how our capsule relates to what was studied.

What is Akkermansia good for?

Akkermansia muciniphila is a bacterium that lives in the mucus layer lining the gut and feeds on mucin, the main component of that mucus. If you are new to it, start with our simple guide to what Akkermansia muciniphila is.

Interest grew because, across groups of people, higher Akkermansia levels tend to go along with healthier metabolic markers. In a 2016 study in France of 49 adults with overweight or obesity, those with more Akkermansia and a richer gut microbiome at the start had the healthiest fasting glucose, triglycerides and body fat distribution, and those with more Akkermansia showed greater improvement in insulin sensitivity markers after six weeks of calorie restriction. That is an association, not proof that Akkermansia caused the difference, which is why supplement trials matter.

Akkermansia muciniphila benefits for the gut lining

This is the benefit with the clearest biological logic. In a 2013 study, a high-fat diet left mice with a mucus layer 46 percent thinner, and daily live Akkermansia for four weeks reversed that loss and normalized the rise in bacterial products reaching the blood, while heat-killed cells did not. In a 2017 mouse study, a protein from the outer membrane of Akkermansia, called Amuc_1100, improved the gut barrier and reproduced part of the effect of the whole bacterium.

In people, the evidence is thinner. In a 2019 trial of adults with overweight or obesity and insulin resistance, pasteurized Akkermansia lowered blood levels of lipopolysaccharide (LPS), a bacterial component used as a marker of gut barrier leakage, compared with placebo, and it did not change the overall makeup of the gut microbiome. That is one small study using an indirect marker, but it fits the animal work.

Akkermansia and metabolic health: what human trials measured

The 2019 Belgian trial is still the most cited. It gave 40 adults with overweight or obesity and insulin resistance a placebo, live cells or pasteurized cells, 10 billion a day, for three months, and 32 finished. Compared with placebo, the pasteurized form raised insulin sensitivity by about 29 percent, lowered fasting insulin by about 34 percent and lowered total cholesterol by about 9 percent. It also lowered blood markers of liver dysfunction and inflammation. The live form moved fewer measures, though it did improve an insulin resistance score.

A 2025 trial in China gave 58 adults with overweight or obesity and type 2 diabetes a live strain (AKK-WST01) or placebo daily for 12 weeks, alongside routine lifestyle advice. Body weight and HbA1c, a measure of average blood sugar over about three months, fell in both groups, with no significant difference between them. The difference appeared in people who started with low Akkermansia levels: in that subgroup the strain took hold well and weight, fat mass and HbA1c fell significantly, while people who started with high levels saw no significant improvement.

A 2026 trial in Ireland and Germany gave 142 adults with metabolic syndrome 30 billion pasteurized cells or placebo daily for four months. Its main measure, whole-body insulin sensitivity, did not differ from placebo. Exploratory analyses found better liver insulin sensitivity in people with prediabetes and in those aged 63 or older, and the clearest changes in people who started with low Akkermansia. Several of the authors work for the company that makes the ingredient.

Akkermansia weight loss: what the evidence shows

In the 2019 trial, the pasteurized group lost about 2.3 kg more than placebo, but the difference was not statistically significant. In the 2025 trial of a live strain, weight fell in both the Akkermansia and placebo groups, with no significant difference between them.

The most interesting result is about keeping weight off. In a 2026 trial in the Netherlands, 90 adults with overweight or obesity first lost weight on an 8-week low-calorie diet, then took pasteurized Akkermansia or placebo daily for 24 weeks while eating a healthy diet freely. The Akkermansia group regained about 1.2 kg on average, compared with 3.2 kg on placebo, which was the main measure of the trial. Several authors work for the company behind the ingredient, and the result needs repeating. It is a weight maintenance finding, and Akkermansia is not a weight-loss product.

Akkermansia and GLP-1

GLP-1 is a gut hormone involved in appetite and blood sugar control, and the target of a class of prescription medicines. The Akkermansia link started in mice: in 2021, researchers identified a protein secreted by Akkermansia, called P9, that was enough on its own to trigger GLP-1 release in gut cells and in mice on a high-fat diet.

Human data are limited and mixed. The 2019 trial measured blood GLP-1 and found no significant change. The 2026 trial of 142 adults found, in exploratory analyses, that the rise in GLP-1 after a glucose drink was larger with pasteurized Akkermansia than with placebo, particularly in people who started with low Akkermansia. That is a signal worth following, not evidence that a supplement works like a GLP-1 medicine. Our capsule is a dietary supplement, not a substitute for any prescription medicine, and it has not been shown to produce the effects of a GLP-1 medicine.

Other Akkermansia benefits being studied

Research is branching out. In a 2024 trial in Korea, 100 adults aged 60 and older took 10 billion pasteurized cells of a different strain (HB05) or placebo daily for 12 weeks. The Akkermansia group improved more than placebo in peak torque of the left leg extensor muscles, a measure of leg strength, and had higher levels of follistatin, a protein that counteracts the muscle-limiting protein myostatin. It is one trial of one strain, so it is a lead rather than a conclusion.

Why your starting Akkermansia level may matter

A thread runs through the newer trials: people who started with low Akkermansia tended to respond more, in both the 2025 live-strain trial and the 2026 metabolic syndrome trial. These were subgroup findings that need confirming, and a stool test is an imperfect way to measure Akkermansia, as we explain in what low Akkermansia on a gut test actually means. Still, they suggest that any benefit may depend on what is already in your gut.

Live vs pasteurized: which form the benefits come from

Most of the encouraging human results above came from pasteurized cells: the 2019 pasteurized group, the two 2026 trials and the 2024 strength trial. Live cells have fewer human trials: the 2019 live group, which moved fewer measures, and the 2025 live-strain trial, where benefits appeared only in people with low starting levels. In mice the picture is split. The 2013 study found that heat-killed cells lost the effect, while the 2017 study found that pasteurization enhanced it. Which form works best in people is still an open question.

Our capsule is a live, microencapsulated strain at 1 billion AFU. That differs from the trials in form (most positive trials used pasteurized cells), in amount (trials used 10 billion to 30 billion cells a day; AFU and cell counts are measured differently, but ours is the smaller number) and in preparation, since none of these trials tested our capsule. Research on a different preparation is not proof of what our capsule does.

Who should check with a physician first

Akkermansia has been well tolerated in the trials so far, with mostly mild digestive side effects. Check with your physician before starting if you are pregnant or breastfeeding, have a weakened immune system or take immunosuppressive medication, are considering it for a child, take prescription medication including GLP-1 or diabetes medicines, or have a digestive or other ongoing health condition. For the full safety picture, see our guide to Akkermansia side effects.

How Vita Bloom fits

Our Akkermansia probiotic provides Akkermansia muciniphila, 1 billion AFU per capsule, as a live, microencapsulated strain in a vegetarian capsule that is shelf-stable at room temperature, with no refrigeration needed. It supports the gut lining and a healthy gut barrier, and supports a balanced gut and everyday digestive comfort.* Take one capsule daily with food, up to two a day, and give it at least 4 to 8 weeks of consistent use before judging results.

Frequently asked questions

What are the main Akkermansia benefits?

The best studied are support for the gut lining and for metabolic markers such as insulin sensitivity and cholesterol. The human evidence comes from a handful of small trials, mostly of pasteurized cells, so it is promising but early.

Does Akkermansia help with weight loss?

Not on its own, based on current trials. Two trials found no significant weight difference from placebo. A 2026 trial found less weight regain after a diet, 1.2 kg versus 3.2 kg over 24 weeks, a weight maintenance finding that needs confirming.

Does Akkermansia increase GLP-1?

In mice, a protein made by Akkermansia triggered GLP-1 release. In people, one trial found no change and another found a larger GLP-1 rise after a glucose drink in exploratory analyses. It is not a substitute for a GLP-1 medicine.

How long does it take to notice Akkermansia benefits?

The trials measured results after 12 weeks to six months, mostly through blood tests rather than anything people felt. Our label says to give it at least 4 to 8 weeks of consistent use before judging results.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.